Share This Page
Suppliers and packagers for CYSTARAN
✉ Email this page to a colleague
CYSTARAN
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Leadiant Biosci Inc | CYSTARAN | cysteamine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 200740 | NDA | Leadiant Biosciences, Inc. | 54482-020-02 | 15 mL in 1 BOTTLE (54482-020-02) | 2012-12-30 |
| Leadiant Biosci Inc | CYSTARAN | cysteamine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 200740 | NDA | Leadiant Biosciences, Inc. | 54482-035-02 | 15 mL in 1 BOTTLE (54482-035-02) | 2012-12-30 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Cystaran (Cysteamine Ophthalmic Solution)
Introduction
Cystaran, commercially known as cysteamine ophthalmic solution, is a prescription medication primarily indicated for the management of cystinosis—a rare genetic disorder characterized by the accumulation of cystine crystals in various tissues, including the eyes. Since its FDA approval in 2013, Cystaran has become a critical therapeutic for patients with cystinosis, particularly for reducing corneal crystal deposits. As demand for this specialized drug escalates, understanding the landscape of suppliers—ranging from active pharmaceutical ingredient (API) producers to finished drug manufacturers—is essential for stakeholders across the supply chain.
Overview of Cystaran and Raw Material Requirements
Cystaran's primary active ingredient, cysteamine hydrochloride, is synthesized through complex chemical processes that require high purity and stringent quality controls. The manufacturing of this API demands raw materials that meet pharmaceutical standards, and the production process is tightly regulated to ensure safety, efficacy, and stability. Furthermore, as an ophthalmic solution, formulation components and preservative agents are critical to product stability and patient tolerability.
Key Suppliers of Cysteamine Hydrochloride (API)
The supply of cysteamine hydrochloride is concentrated among a select group of manufacturers globally. These suppliers primarily serve pharmaceutical companies that produce cystaran and other cystine-depleting therapies.
Major API Manufacturers
-
Pharmaceutical Raw Material Suppliers in China and India
China and India dominate global API production for cysteamine hydrochloride, primarily through major chemical manufacturers recognized for high-volume, cost-competitive output. Companies such as Jiangsu Hengrui Medicine Co., Ltd. and Dr. Reddy’s Laboratories are among the key players supplying bulk cysteamine hydrochloride, often to formulators who develop ophthalmic solutions (see [1], [2]).
-
European and North American API Manufacturers
European companies like MEGGLE (Germany) and North American firms such as Mka Laboratories have specialized in high-grade, pharma-compliant cysteamine hydrochloride for niche or high-purity applications. These companies often cater to specialty markets where regulatory standards are particularly stringent.
Emerging Suppliers and Contract Manufacturers
Clinical and commercial demand for cysteamine products has prompted the rise of contract manufacturing organizations (CMOs) specializing in sterile injectable and ophthalmic formulations, often sourcing API from established suppliers and ensuring quality through rigorous validation processes.
Finished Goods Manufacturers
The original approved product, Cystaran, was developed and manufactured by $\text{Specialized pharmaceutical companies}$ with expertise in ophthalmic drugs:
- InSite Vision (now inactive in this segment), initially marketed Cystaran.
- Other potential convergences involve generic manufacturers seeking FDA approval for cysteamine ophthalmic solutions, leveraging APIs sourced from global suppliers.
Supply Chain Considerations
Several factors influence supplier selection and supply chain robustness:
- Regulatory compliance: Suppliers must demonstrate adherence to cGMP standards, with stringent quality controls verified via an API certificate of analysis (COA).
- Supply stability: Given the rarity of cystinosis, consistent global supplies are critical. Politics, manufacturing disruptions, or regulatory changes in key supplier countries can impact availability.
- Pricing and capacity: Indian and Chinese API producers typically offer competitive pricing, but capacity constraints or export restrictions can influence affordability and availability.
- Quality assurance: Suppliers of cysteamine hydrochloride must provide comprehensive documentation, stability data, and batch consistency, vital for ophthalmic formulation safety.
Market and Regulatory Landscape
While the central supply of cysteamine hydrochloride largely depends on Asian suppliers, multiple regulatory pathways exist to facilitate entry and supply in developed markets:
- FDA Approved API Sources: Suppliers meeting U.S. Pharmacopeia (USP) standards with validated manufacturing processes.
- Global Good Manufacturing Practices (GMP): Compliance with international standards (ICH Q7) to ensure global market access.
Challenges in the Supply Chain
- Limited supplier diversity: Concentration among AAPI manufacturers heightens supply risks.
- Economic and geopolitical factors: Tariffs, trade disputes, or export bans can disrupt supply.
- Need for high purity: Strict purity standards restrict supplier pool to those capable of high-quality manufacturing.
Future Directions in Supply
Emerging markets are increasing investment in cysteamine API production, aiming to diversify supply sources. Additionally, development of synthetic routes and process innovations could lower costs and improve scalability.
Key Industry Players and Considerations
| Company | Region | Role | Notes |
|---|---|---|---|
| Jiangsu Hengrui Medicine Co., Ltd. | China | API Supplier | Large-scale API production, exports globally |
| Dr. Reddy’s Laboratories | India | API Provider | Known for cGMP API, supply to global formulators |
| Mka Laboratories | North America | API Producer | High-purity API for specialty applications |
| Meggle | Germany | API Manufacturer | Focused on high-quality pharma-grade API |
Conclusion
Securing a reliable supply of cysteamine hydrochloride remains critical for the continued availability of Cystaran. The global landscape is characterized by a handful of dominant API producers, primarily located in Asia, with high regulatory standards necessitating rigorous quality oversight. Pharmaceutical companies and formulators must establish vetted, compliant sourcing channels to mitigate supply risks, especially given the rare indication and limited market size. As the demand for cysteamine ophthalmic solutions grows and new formulations enter development, supply chain resilience will be pivotal in ensuring patient access and market stability.
Key Takeaways
- The primary suppliers of cysteamine hydrochloride are predominantly located in China and India, with specialized sources in Europe and North America.
- Maintaining high-quality, cGMP-compliant API supplies is vital, necessitating thorough supplier qualification.
- Supply risks stem from geopolitical factors, capacity constraints, and limited supplier diversity.
- Industry trends point toward increased manufacturing capacity in emerging markets and potential process innovations.
- Buyers should prioritize suppliers with proven compliance records, stable capacity, and transparent quality assurance practices.
FAQs
1. Who are the main API suppliers for cysteamine hydrochloride?
The leading API producers are mainly Chinese and Indian manufacturers such as Jiangsu Hengrui Medicine and Dr. Reddy’s Laboratories, known for high-volume, cost-effective production.
2. How does supply chain risk affect the availability of Cystaran?
Concentration of supply sources and geopolitical or trade disruptions can lead to shortages, impacting patient access and treatment continuity.
3. What quality standards must cysteamine API suppliers meet?
Suppliers must adhere to cGMP standards, provide comprehensive COAs, and meet pharmacopeial standards such as USP or Ph. Eur.
4. Are there alternatives if primary suppliers face disruption?
Yes, emerging manufacturers in Asia and Europe are expanding capacity, and formulation companies may seek alternative sources or develop synthetic routes.
5. What does the future hold for cysteamine API supply?
Increased capacity in emerging markets, process innovations, and strategic supplier diversification are expected to enhance supply stability and reduce costs.
References
- [1] U.S. FDA Drug Approvals and Cystinosis Treatment Data.
- [2] Global API Market Reports, Industry Analysis on Cysteamine Hydrochloride.
More… ↓
